Earnings call transcript: RTX Q3 2025 sees revenue rise, stock gains 2.35%

RTX reported robust Q3 2025 earnings, showcasing a 10% quarter-on-quarter revenue increase and a significant EBITDA turnaround to CHF 22 million from a prior-year loss, while maintaining gross margins above 50%. This strong performance, driven by its wireless secure communication technology and strategic partnerships, has propelled the stock near its 52-week high with a 40.87% year-to-date return, prompting the initiation of a CHF 20 million share buyback program. The company projects continued growth and aims for CHF 1 billion in revenue, actively diversifying its supply chain from China, though it acknowledges ongoing logistical and currency challenges.

Analysis

RTX A/S reported a robust third quarter for fiscal year 2025, demonstrating significant operational improvement and positive momentum. Revenue grew 10% quarter-on-quarter on a constant currency basis, and the company achieved a notable turnaround in profitability with an EBITDA of CHF 22 million, compared to a loss of CHF 20 million in the prior-year period. This was driven by strength in the core Enterprise segment, which is seeing demand patterns normalize, and impressive growth in the high-margin Healthcare division through its partnership with Philips. Gross margins were sustained above 50%, reflecting a favorable product mix and improved planning. The ProAudio segment remains in transition, with a strategic shift to a scalable module-based model causing a near-term revenue decline to CHF 56 million from CHF 92 million year-over-year, though management anticipates this business has bottomed out. The company's financial health is solid, evidenced by a CHF 35 million reduction in component inventory, net liquidity of CHF 120 million, and the subsequent launch of a CHF 20 million share buyback program. While management maintains an ambitious long-term revenue goal of CHF 1 billion, they acknowledge headwinds from a weaker U.S. dollar and logistical challenges associated with diversifying the supply chain away from China.

Key Decisions for Investors

• The strong Q3 results and new CHF 20 million share buyback support a positive outlook, but investors should scrutinize the execution and timeline for the ambitious CHF 1 billion revenue target under the new CEO.
• Monitor the performance of the high-margin Healthcare segment for sustained growth and the ProAudio segment for signs of a revenue bottom, as these are critical to validating the long-term growth narrative and justifying the stock's valuation near its 52-week high.
• Investors should price in the explicit risks mentioned by management, including foreign exchange pressure from a weaker U.S. dollar and potential margin impacts from the ongoing supply chain shift out of China.
• Evaluate the company's ability to expand its Healthcare customer base beyond the core Philips partnership, as this is crucial for long-term growth but involves significant lead times and execution risk.